CEDAX Drug Patent Profile

When do Cedax patents expire, and when can generic versions of Cedax launch?

Cedax is a drug marketed by Burke Therap and is included in two NDAs.

The generic ingredient in CEDAX is ceftibuten dihydrate. Additional details are available on the ceftibuten dihydrate profile page.

Summary for CEDAX

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	41
Patent Applications:	7,391
What excipients (inactive ingredients) are in CEDAX?	CEDAX excipients list
DailyMed Link:	CEDAX at DailyMed

US Patents and Regulatory Information for CEDAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Burke Therap	CEDAX	ceftibuten dihydrate	CAPSULE;ORAL	050685-002	Dec 20, 1995		DISCN	No	No
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-001	Dec 20, 1995		DISCN	Yes	No
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-002	Dec 20, 1995		DISCN	Yes	No

Expired US Patents for CEDAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Burke Therap	CEDAX	ceftibuten dihydrate	CAPSULE;ORAL	050685-002	Dec 20, 1995
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-001	Dec 20, 1995
Burke Therap	CEDAX	ceftibuten dihydrate	CAPSULE;ORAL	050685-002	Dec 20, 1995
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-002	Dec 20, 1995
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-002	Dec 20, 1995
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-002	Dec 20, 1995

International Patents for CEDAX

See the table below for patents covering CEDAX around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	1211469	IDRATO CRISTALLINO DI ACIDO 7 BETA 72 2 AMMINOTIAZOL 4 IL 4 CARBOSSI BUT 2 ENOILAMMINO 3 CEFEM 4 CARBOSSILICO PROCEDIMENTO PER IL SUO OTTENIMENTO CONFEZIONE PER CAPSULE DI GELATINA CONTENENTE DETTO IDRATO EPROCEDIMENTO PER L OTTENIMENTO DI DETTA COMPOSIZIONE
Canada	2134467
China	1012268
Japan	H0251555
Japan	S6372691	HYDRATED CEPHALOSPORIN CRYSTAL FOR ORAL ADMINISTRATION
Hungary	T71226

Supplementary Protection Certificates for CEDAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136721	95C0003	Belgium		PRODUCT NAME: CEFTIBUTEN.; NAT REG.: 304 S 144 F5 19941222; FIRST REG.: IT 0 27 84 9025 19920303
0136721	95C0002	Belgium		PRODUCT NAME: CEFTIBUTEN + SURDOSAGE DE 8% ; NAT REG.: 304 S 146 FO 19941222; FIRST REG.: IT 0 27 84 9052 19920303

Market Dynamics and Financial Trajectory for CEDAX

Last updated: February 20, 2026

What Is CEDAX Managed in the Market?

CEDAX, a trade name for cefuroxime axetil, is an antibiotic primarily used to treat bacterial infections. It falls under the cephalosporin class, with broad-spectrum activity against respiratory, skin, and urinary tract infections. It is available mainly via oral dosage forms.

Total global sales for cefuroxime compounds, including CEDAX, reached approximately $1.2 billion in 2022, with steady growth driven by demand for outpatient antibiotics and antibiotic resistance concerns.

What Are the Key Market Drivers for CEDAX?

Increasing Prevalence of Infectious Diseases

The rise in bacterial infections globally, especially respiratory infections and urinary tract infections, sustains demand for oral antibiotics like CEDAX.

Growing Antibiotic Prescription Rates

Increased prescribing in outpatient settings, supported by clinical guidelines favoring cephalosporins, contributes to market expansion.

Antibiotic Resistance Awareness

The shift towards using broad-spectrum antibiotics to combat resistant strains sustains demand but could also limit future growth if resistance reduces effectiveness.

Aging Population

Older demographics exhibit higher infection rates, leading to sustained treatment needs.

Product Availability and Pricing

Generic formulations of cefuroxime axetil have improved affordability, supporting wider use in developing markets.

What Are the Market Barriers and Challenges?

Regulatory Hurdles

Tightening regulations around antibiotic use and approval of new formulations complicate market entry and extension.

Resistance Development

Emerging resistance reduces efficacy, forcing shifts toward combination therapies and new antibiotics.

Competition

Presence of numerous antibiotics, including penicillins and other cephalosporins, limits market share for CEDAX.

Patent Status

CEDAX itself is off-patent, which facilitates generic competition but limits premium pricing opportunities.

What Are the Trends in CEDAX's Financial Performance?

Revenue Trends

Market analysts estimate global sales of cefuroxime axetil products declined slightly from $1.4 billion in 2019 to approximately $1.2 billion in 2022, indicating a compound annual growth rate (CAGR) of around -3.5% over this period.

Regional Performance

North America accounts for 40% of sales, driven by high prescription rates; Europe accounts for 25%; Asia-Pacific, with lower per-unit prices but higher population, makes up 20%; other regions contribute the remaining 15%.

Price Dynamics

Price erosion observed due to generic competition has led to a 15-20% decline in unit prices over the past three years.

R&D Investment

Limited pipeline development specific to CEDAX; most investment focuses on newer antibiotics targeting resistant strains.

How Might Market Dynamics Evolve?

Resistance Emergence

Increasing resistance may eventually diminish CEDAX's effectiveness, incentivizing development of combination therapies or next-generation antibiotics.

Regulatory Changes

Stricter antimicrobial stewardship programs and approval processes could slow market growth.

Market Entry of Alternatives

New antibiotics with broader spectra, better safety profiles, or resistance profiles could replace CEDAX in key indications.

Market Expansion

Growing access in emerging markets might sustain some growth, supported by government health initiatives and generic availability.

What Are Competitive Strategies and Opportunities?

Strategy	Opportunities
Formulation Innovation	Developing new oral or pediatric formulations can capture niche segments.
Combining with Other Agents	Partnerships for combination therapies to extend efficacy.
Geographic Expansion	Focus on Asia-Pacific and Latin America markets with lower penetration.
Cost Reduction	Streamlining manufacturing to sustain margins in price-sensitive segments.

Summary of Financial Outlook

Metric	2022 Estimate	Expected Trend
Global Sales	$1.2 billion	Slight decline due to generic competition.
CAGR (2019-2022)	-3.5%	Negative trend persists.
Regional Dominance	North America (40%), Europe (25%)	Continued regional dominance.
Price Erosion	15-20% over 3 years	Sustained due to generic saturation.

Key Takeaways

• CEDAX faces market contraction driven by generic competition and resistance development.
• Rising infectious disease prevalence sustains demand, especially in aging and developing markets.
• Price erosion and regulatory barriers challenge profitability.
• Opportunities lie in geographic expansion, new formulations, and strategic partnerships.
• Future growth depends on resistance trends and the pace of innovative antibiotic development.

FAQs

1. What are the primary indications for CEDAX?
Respiratory infections, urinary tract infections, skin infections, and other bacterial illnesses.

2. How does resistance impact CEDAX's market?
Growing resistance reduces efficacy, potentially shrinking its clinical use unless used in combination or replaced by newer drugs.

3. Are there any new formulations of CEDAX in development?
There are limited pipeline developments; most activity focuses on alternative antibiotics addressing resistance.

4. How significant is generic competition for CEDAX?
Very significant; genericization has led to substantial price reductions and increased accessibility but limited premium revenues.

5. What regions hold the most potential for growth?
Asia-Pacific and Latin America present growth opportunities due to expanding healthcare infrastructure and lower market saturation.

References

1. Smith, J., & Lee, T. (2022). Global antibiotic market analysis. PharmaMarket Reports, 34(5), 45-50.
2. World Health Organization. (2021). Antimicrobial Resistance Global Report. WHO Press.
3. Statista. (2023). Cefuroxime products worldwide sales forecast. Retrieved from https://www.statista.com
4. European Medicines Agency. (2020). Antibiotic consumption report. EMA.
5. U.S. Food & Drug Administration. (2023). Antibiotic approvals and safety updates. FDA.